Weller I V, Carreno V, Fowler M J, Monjardino J, Makinen D, Varghese Z, Sweny P, Thomas H C, Sherlock S
J Antimicrob Chemother. 1983 Mar;11(3):223-31. doi: 10.1093/jac/11.3.223.
Six patients with hepatitis B virus (HBV) related chronic liver disease were treated with acyclovir, 5-15 mg/kg 8 hourly, given as an iv bolus or iv infusion over 1 h for up to 7 days. Two patients treated with 10 and 15 mg/kg 8 hourly showed a decrease in HBV-DNA polymerase and HBV-DNA when mean trough acyclovir plasma concentrations of 5.0 +/- 0.6 and 13.2 +/- 3.0 microM were attained. Inhibition of viral replication was not seen in patients treated with lower doses. Transient renal impairment was seen in two patients who received high dosage by the iv bolus mode of administration. This complication may be prevented by a high oral fluid intake or iv infusion of the drug over 1 h. Further study with acyclovir 15 mg/kg 8-hourly given as an iv infusion for longer periods is warranted.
6例乙型肝炎病毒（HBV）相关慢性肝病患者接受阿昔洛韦治疗，剂量为5 - 15mg/kg，每8小时一次，静脉推注或在1小时内静脉输注，持续7天。2例每8小时接受10mg/kg和15mg/kg治疗的患者，当阿昔洛韦血浆平均谷浓度达到5.0±0.6和13.2±3.0微摩尔时，HBV - DNA聚合酶和HBV - DNA水平下降。低剂量治疗的患者未观察到病毒复制受到抑制。2例通过静脉推注方式接受高剂量治疗的患者出现了短暂性肾功能损害。通过大量口服液体或在1小时内静脉输注该药物可预防此并发症。有必要进一步研究以每8小时15mg/kg的剂量静脉输注阿昔洛韦更长时间的情况。
